Abstract
Ionic liquids (ILs) recently draw attention for addressing unmet needs in biomedicines. By converting solidsinto liquids, ILs are emerging as novel platforms to overcome some critical drawbacks associated with theapplication of solid or crystalline active pharmaceutical ingredients (APIs). ILs have shown promise in liquidizing orsolubilizing APIs, or as green solvents, novel permeation enhancers or active ingredients, alone or synergisticallywith APIs. Meanwhile, challenges turn up in company with the deepening understanding of ILs as drug deliverycarrier systems. This perspective aims to provide a sketchy overview on the status quo with specific attention paidto new problems arising from the utilization of ILs-based technologies in drug delivery.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call